[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100464527":3},{"organization":4,"outcomesModule":7,"designInfo":43,"detailedDescription":15,"studyPopulation":15,"armGroups":49,"interventions":60,"overallOfficials":15,"centralContacts":66,"locations":72,"responsibleParty":92,"collaborators":15,"id":96,"slug":15,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":15,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":15,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":15,"overallStatus":75,"whyStopped":15,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Charite University, Berlin, Germany","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":15},[9,13,16,20,23,26,29,32,35,38,41],{"measure":10,"description":11,"timeFrame":12},"Immunological laboratory","T-Cells (CD3), B-Cells (CD19), Natural Killer Cells (CD16), T-helper cells (CD4), cytotoxic T-cells (CD8), CD4\u002FCD8 ratio, interleukin 4, interferon gamma","Change from Baseline and after 4 weeks",{"measure":14,"description":15,"timeFrame":12},"Blood pressure at rest (systolic and diastolic)",null,{"measure":17,"description":18,"timeFrame":19},"Hospital Anxiety and Depression Scale (HADS-D)","Change","Change from HADS-D Baseline, after 4 weeks and 12 weeks",{"measure":21,"description":18,"timeFrame":22},"Self-Efficacy Scale (ASKU)","Change from ASKU Baseline, after 4 weeks and 12 weeks",{"measure":24,"description":18,"timeFrame":25},"WHO-Five Well-Being Index (WHO-5)","Change from WHO-5 Baseline, after 4 weeks and 12 weeks",{"measure":27,"description":18,"timeFrame":28},"Perceived Stress Scale (PSS-10)","Change from PSS-10 Baseline, after 4 weeks and 12 weeks",{"measure":30,"description":18,"timeFrame":31},"Flourishing Scale (FS-D)","Change from FS-D Baseline, after 4 weeks and 12 weeks",{"measure":33,"description":18,"timeFrame":34},"Insomnia Severity Index (ISI-D)","Change from ISI-D Baseline, after 4 weeks and 12 weeks",{"measure":36,"description":18,"timeFrame":37},"Short Form (SF-36)","Change from SF-36 Baseline, after 4 weeks and 12 weeks",{"measure":39,"description":18,"timeFrame":40},"Von Zerssen somatic complaint list (B-LR and B-LR')","Change from B-LR and B-LR' Baseline, after 4 weeks and 12 weeks",{"measure":42,"description":18,"timeFrame":12},"Heart rate variability",{"allocation":44,"interventionModel":45,"interventionModelDescription":15,"primaryPurpose":46,"observationalModel":15,"timePerspective":15,"maskingInfo":47},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":48,"maskingDescription":15,"whoMasked":15},"NONE",[50,56],{"label":51,"type":52,"description":53,"interventionNames":54},"Vital shower","ACTIVE_COMPARATOR","Participants receive a prototype\u002Fshower head from Hansgrohe and training including a handout. After installation, participants are asked to shower daily for four weeks according to a predefined shower protocol.",[55],"Device: Hansgrohe prototype\u002Fshower head",{"label":57,"type":58,"description":59,"interventionNames":15},"Regular shower","NO_INTERVENTION","Participants are advised not to change their showering behaviour; at the end of the study, the participants receive an offer of a shower head for free.",[61],{"type":62,"name":63,"description":64,"armGroupLabels":65,"otherNames":15},"DEVICE","Hansgrohe prototype\u002Fshower head","Start of the shower with warm comfort temperature and usual body cleansing. Then the Vital shower is carried out for a total of 3-5 minutes, followed optionally by another warm shower with 30 seconds or direct transition to a classic cold shower for 30- 60 seconds",[51],[67],{"name":68,"role":69,"phone":70,"phoneExt":15,"email":71},"Miriam Rösner","CONTACT","03080505682","miriam.roesner@immanuelalbertinen.de",[73],{"facility":74,"status":75,"city":76,"state":77,"zip":78,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":86,"contacts":87},"Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus","RECRUITING","Berlin","State of Berlin","14163","Germany","DE",{"type":82,"coordinates":83},"Point",[84,85],13.41053,52.52437,{"lat":85,"lon":84},[88],{"name":89,"role":69,"phone":90,"phoneExt":15,"email":91},"Andreas Michalsen, Prof. Dr.","+49 (0)30 - 80505 - 691","a.michalsen@immanuel.de",{"type":93,"investigatorFullName":94,"investigatorTitle":95,"investigatorAffiliation":5,"oldNameTitle":15,"oldOrganization":15},"PRINCIPAL_INVESTIGATOR","Andreas Michalsen","Prof. Dr. Andreas Michalsen","100464527",false,"NCT05328856","Effects of Vital Shower on Quality of Life, Immune Function, Cardiovascular Regulation and Well-being","An Randomised Controlled Trial on the Effects of Vital Shower (Hansgrohe) on Quality of Life, Immune Function, Cardiovascular Regulation and Well-being","Inclusion Criteria:\n\n* Female and male patients between 18 and 70 years of age\n\nExclusion Criteria:\n\n* Bad general condition\n* Serious acute or chronic comorbidity\n* Pregnancy and breast feeding period\u002F in the next 6 months\n* Participation in a clinical trial within the last 3 months before enrollment\n* Simultaneous participation in another clinical trial\n* Raynaud's disease or cold agglutinin disease\n* Severe mental illness\n* Insufficiently treated dermatological diseases (e.g. neurodermatitis, psoriasis)\n* Non-compatible sanitary shower or bath devices",true,"ALL","18 Years","70 Years",{"count":107,"type":108},50,"ESTIMATED","INTERVENTIONAL",[111],"NA","The aim of this exploratory randomized controlled clinical study is to evaluate the health-promoting effects of Kneipp hydrotherapy, in the form of the Vital Shower in a four-week daily application.",[114],"General Population","2025-03-04",{"date":117,"type":118},"2025-03-06","ACTUAL",{"date":120,"type":118},"2022-05-25",{"date":122,"type":108},"2025-12-31",{"name":5,"class":6},1]